Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
Jeffrey R. Infante(Tennessee Oncology), Leslie A. Fecher(University of Pennsylvania), Gerald S. Falchook(The University of Texas MD Anderson Cancer Center), Sujatha Nallapareddy(University of Colorado Cancer Center), Michael S. Gordon(Pinnacle Oncology Hematology), Carlos Becerra(Texas Oncology), Douglas J. DeMarini(GlaxoSmithKline (United States)), Donna S. Cox(GlaxoSmithKline (United States)), Yanmei Xu(GlaxoSmithKline (United States)), Shannon R. Morris(GlaxoSmithKline (United States)), Vijay Peddareddigari(GlaxoSmithKline (United States)), Ngocdiep T. Le(GlaxoSmithKline (United States)), Lowell L. Hart(Sarah Cannon), Johanna C. Bendell(Sarah Cannon), Gail Eckhardt(University of Colorado Cancer Center), Razelle Kurzrock(The University of Texas MD Anderson Cancer Center), Keith T. Flaherty(University of Pennsylvania), Howard A. Burris(Tennessee Oncology), Wells A. Messersmith(University of Colorado Denver)
Cited by 557
Abstract
Related Papers
No related papers found
Powered by citation graph analysis